dapi has been researched along with Prostatic Hyperplasia in 1 studies
DAPI: RN given refers to parent cpd.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hennenberg, M | 1 |
| Schreiber, A | 1 |
| Ciotkowska, A | 1 |
| Rutz, B | 1 |
| Waidelich, R | 1 |
| Strittmatter, F | 1 |
| Stief, CG | 1 |
| Gratzke, C | 1 |
1 other study available for dapi and Prostatic Hyperplasia
| Article | Year |
|---|---|
Cooperative effects of EGF, FGF, and TGF-β1 in prostate stromal cells are different from responses to single growth factors.
Topics: Blotting, Western; Cell Line; Epidermal Growth Factor; Fibroblast Growth Factors; Fluorescence; Huma | 2015 |